In murine models of melanoma and lung cancer, genetic silencing of LRG-1 or pharmacological inhibition have shown to both improve tumor vessel function, to slowdown tumor growth and metastasis, and to improve the delivery and efficacy of cytotoxic drugs and immunotherapies including immune check point inhibitors [21, 26, 46, 47]. The gene discussed is LRG1; the disease is melanoma.